C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis.
作者信息
Han Runhong, Hu Shuai, Qin Weisong, Shi Jinsong, Hou Qin, Wang Xia, Xu Xiaodong, Zhang Minchao, Zeng Caihong, Liu Zhihong, Bao Hao
出版信息
JCI Insight. 2019 Jul 11;4(13). doi: 10.1172/jci.insight.130986.
Abstract
摘要
相似文献
1
C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis.C3a和可溶性尿激酶型纤溶酶原激活物受体（suPAR）驱动局灶节段性肾小球硬化肾小管细胞中多功能蛋白聚糖V1的表达。
JCI Insight. 2019 Jul 11;4(13). doi: 10.1172/jci.insight.130986.
2
C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis.C3a 和 suPAR 驱动局灶节段性肾小球硬化症中肾小管细胞的 versican V1 表达。
JCI Insight. 2019 Apr 4;4(7). doi: 10.1172/jci.insight.122912.
3
Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.可溶性尿激酶受体水平与IgA肾病中的局灶节段性肾小球硬化病变相关：一项来自中国的队列研究
PLoS One. 2015 Sep 18;10(9):e0138718. doi: 10.1371/journal.pone.0138718. eCollection 2015.
4
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.鉴定原发性局灶节段性肾小球硬化的潜在生物标志物及其与移植后复发的关系。
Clin Transplant. 2019 Mar;33(3):e13487. doi: 10.1111/ctr.13487. Epub 2019 Feb 21.
5
[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].[可溶性尿激酶受体血清水平在特发性与继发性局灶节段性肾小球硬化鉴别诊断中的价值]
Nefrologia. 2014;34(1):53-61. doi: 10.3265/Nefrologia.pre2013.Oct.12272.
6
Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.蛋白A免疫吸附不能显著清除复发性局灶节段性肾小球硬化症患者血清中的尿激酶可溶性受体。
Nephrol Dial Transplant. 2014 Feb;29(2):458-63. doi: 10.1093/ndt/gft453. Epub 2013 Nov 13.
7
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.血清可溶性尿激酶受体水平不能区分局灶节段性肾小球硬化与儿童肾病综合征的其他病因。
Kidney Int. 2014 Mar;85(3):649-58. doi: 10.1038/ki.2013.546. Epub 2014 Jan 15.
8
Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb.使用CytoSorb去除局灶节段性肾小球硬化（FSGS）因子可溶性尿激酶型纤溶酶原激活物受体（suPAR）。
J Clin Apher. 2017 Dec;32(6):444-452. doi: 10.1002/jca.21538. Epub 2017 Mar 29.
9
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.可溶性尿激酶型纤溶酶原激活物受体不是局灶节段性肾小球硬化的临床标志物。
Kidney Int. 2014 Mar;85(3):636-40. doi: 10.1038/ki.2013.505. Epub 2014 Jan 8.
10
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.采用强化血浆置换及可溶性尿激酶型纤溶酶原激活物受体介导的足细胞β3整合素激活同步监测治疗复发性原发性局灶节段性肾小球硬化症
Transplantation. 2015 Dec;99(12):2593-7. doi: 10.1097/TP.0000000000000914.
引用本文的文献
1
Hemoglobin-associated in proximal tubule cells can be used as a biomarker for idiopathic membranous nephropathy.近端肾小管细胞中与血红蛋白相关的物质可作为特发性膜性肾病的生物标志物。
Front Med (Lausanne). 2025 Jun 11;12:1574852. doi: 10.3389/fmed.2025.1574852. eCollection 2025.
2
The predictive value of suPAR for glomerular segmental sclerosis lesions in renal pathology.suPAR在肾脏病理学中对肾小球节段性硬化病变的预测价值。
Ren Fail. 2025 Dec;47(1):2498628. doi: 10.1080/0886022X.2025.2498628. Epub 2025 May 13.
3
Complement and Podocytopathies: Do We Have a New Biomarker?补体与足细胞病：我们有新的生物标志物了吗？
Kidney Int Rep. 2024 Jan 29;9(3):520-522. doi: 10.1016/j.ekir.2024.01.037. eCollection 2024 Mar.
4
Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.阿米洛利减少肾小球蛋白尿中尿激酶/纤溶酶原驱动的管腔内补体激活。
J Am Soc Nephrol. 2024 Apr 1;35(4):410-425. doi: 10.1681/ASN.0000000000000312. Epub 2024 Jan 23.
5
Urinary matrix metalloproteinase-7 is a sensitive biomarker to evaluate renal tubular injury in patients with minimal change disease and focal segmental glomerulosclerosis.尿基质金属蛋白酶-7是评估微小病变病和局灶节段性肾小球硬化症患者肾小管损伤的敏感生物标志物。
Clin Kidney J. 2023 Feb 10;17(1):sfad027. doi: 10.1093/ckj/sfad027. eCollection 2024 Jan.
6
Single-cell transcriptome analysis of a rat model of bilateral renal ischemia-reperfusion injury.双侧肾缺血再灌注损伤大鼠模型的单细胞转录组分析
Biochem Biophys Rep. 2023 Feb 1;33:101433. doi: 10.1016/j.bbrep.2023.101433. eCollection 2023 Mar.
7
The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.维生素 D 对 COVID-19 中 suPAR 相关 AKI 的作用视角。
Int J Mol Sci. 2022 Sep 14;23(18):10725. doi: 10.3390/ijms231810725.
8
Early, Noninvasive Clinical Indicators of Kidney Prognosis in Primary Nephrotic Syndrome: A Retrospective Exploratory Study.原发性肾病综合征肾脏预后的早期非侵入性临床指标：一项回顾性探索性研究
Int J Nephrol. 2022 Aug 9;2022:2718810. doi: 10.1155/2022/2718810. eCollection 2022.
9
suPAR: An Inflammatory Mediator for Kidneys.可溶性尿激酶型纤溶酶原激活物受体：肾脏的一种炎症介质。
Kidney Dis (Basel). 2022 Jun 8;8(4):265-274. doi: 10.1159/000524965. eCollection 2022 Jul.
10
Identification and external validation of the hub genes associated with cardiorenal syndrome through time-series and network analyses.通过时间序列和网络分析鉴定和验证与心肾综合征相关的枢纽基因。
Aging (Albany NY). 2022 Feb 8;14(3):1351-1373. doi: 10.18632/aging.203878.
Zotero 插件